STOCK TITAN

Stoke Therapeutics to Present at Upcoming Investor Conferences in March

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that management will present at the following upcoming investor conferences:

TD Cowen 45th Annual Healthcare Conference
Date: Wednesday, March 5, 2025
Time: 9:50 a.m. ET

Leerink Partners Global Healthcare Conference
Date: Monday, March 10, 2025
Time: 10:40 a.m. ET

Live webcasts of each event, along with archived replays, will be available in the Investors & News section of Stoke’s website at https://investor.stoketherapeutics.com/.

About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is expected to enter Phase 3 development in 2025. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for the Company’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/.

Stoke Media & Investor Contacts:

Dawn Kalmar

Chief Communications Officer

dkalmar@stoketherapeutics.com

781-303-8302

Doug Snow

Director, Communications & Investor Relations

IR@stoketherapeutics.com

508-642-6485

Source: Stoke Therapeutics, Inc.

Stoke Therapeutics

NASDAQ:STOK

STOK Rankings

STOK Latest News

STOK Stock Data

415.86M
52.01M
4.67%
110.52%
21.1%
Biotechnology
Pharmaceutical Preparations
Link
United States
BEDFORD